SRSF2 and acute myeloid leukemia: We discovered that RKI-1447, Rho-associated coiled-coil containing protein kinase inhibitor, significantly inhibited SRSF2 Mut cells lines in vitro and also targeted primary human AML cells carrying SRSF2 mutations in a PDX model (Figure 2).